This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Curis Announces Appointment Of Maurizio Voi, M.D. As Chief Medical And Chief Development Officer

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the appointment of Maurizio Voi, M.D., as Chief Medical and Chief Development Officer. Dr. Voi will be responsible for the Company's development, clinical trial and regulatory affairs operations, as well as biomarker and translational medicine activities.

Dr. Voi brings to Curis significant experience in targeted oncology drug development, most recently as Vice President of Clinical Development and Medical Affairs for the Oncology Business Unit at Pfizer’s Global Research and Development site in New York. Dr. Voi joined Pfizer in 2009 as Thoracic Tumor Strategy Team Leader for Oncology. In this role, he was responsible for developing strategic plans for assets within the Pfizer portfolio for the treatment of thoracic cancers, with a special emphasis on identifying patient populations most likely to respond to targeted agents by concurrently developing compounds and diagnostics, including XALKORI® (crizotinib), an ALK inhibitor for the treatment of ALK+ advanced non-small cell lung cancer that was granted FDA approval earlier this year.

"We look forward to benefitting from Maurizio’s depth and breadth of oncology product development experience as we seek to advance the development of our proprietary cancer drug candidates including CUDC-101, our first-in-class small molecule inhibitor of EGFR, Her2 and HDAC, CUDC-907, our dual PI3 kinase and HDAC inhibitor that is approaching clinical development, as well as our earlier-stage product candidates," said Dan Passeri, chief executive officer of Curis. "We anticipate that his in-depth experience with the development of several approved targeted cancer agents and understanding of the importance of translational medicine and molecular biology in current cancer treatments, combined with his U.S. and international experience, will greatly strengthen our management team and enhance our capabilities.”

"I am excited about working with Curis’ promising pipeline of cancer drug candidates," said Dr. Voi. "These novel oncology therapeutics are all based on Curis’ proven chemistry capabilities and expertise in cancer pathway network biology. I am looking forward to working with the Curis team to drive the development-stage assets in clinical testing as well as to working closely with the research team in its efforts to generate additional novel molecules for cancer."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.46 0.47%
FB $100.65 -3.30%
GOOG $676.93 -0.97%
TSLA $151.27 -7.00%
YHOO $26.82 -4.10%


Chart of I:DJI
DOW 15,905.63 -299.34 -1.85%
S&P 500 1,843.38 -36.67 -1.95%
NASDAQ 4,260.0340 -103.11 -2.36%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs